IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings
IA-2 has been identified as an autoantigen that is recognized by immunoglobulins from insulin-dependent diabetic (IDDM) patients. Using a liquid phase radiobinding assay, we performed an IA-2-autoantibody (IA-2-Ab) assay in 474 IDDM patients and 482 non-diabetic control subjects aged 0–39 years. IA-2-Ab were detected in 58 % of the patients and 0.8 % of control subjects. Their prevalence in patients was lower than that of islet cell autoantibodies (ICA; 73 %) or glutamic acid decarboxylase (Mr 65 kDa)-autoantibodies (GAD65-Ab; 82 %) but higher than that of insulin autoantibodies (IAA; 42 %). I... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Text |
| Erscheinungsdatum: | 1997 |
| Schlagwörter: | A100 - Pre-clinical medicine / adolescent / adult / Age of Onset / article / Autoantibodies / autoantibody / Belgium / Biological Markers / Child / Cohort Studies / controlled study / Diabetes Mellitus / Female / genetic susceptibility / Glutamate Decarboxylase / HLA-D Antigens / human / Humans / insulin antibody / insulin dependent diabetes mellitus / Islets of Langerhans / major clinical study / Male / Nuclear Family / prediction / Preschool / Prevalence / priority journal / protein tyrosine phosphatase / Type 1 |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-26573438 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://figshare.com/articles/journal_contribution/IA-2-autoantibodies_complement_GAD65-autoantibodies_in_new-onset_IDDM_patients_and_help_predict_impending_diabetes_in_their_siblings/24342544 |
